CST, 79092S, KIAA1549 Antibody

Polyclonal Antibody for studying KIAA1549. Validated for Western Blotting,Immunoprecipitation. Highly specific and rigorously validated in-house, KIAA1549 Antibody (CST #79092) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation Specificity / Sensitivity KIAA1549 Antibody recognizes endogenous levels of total KIAA1549 protein. This antibody detects KIAA1549::B-Raf fusion proteins containing KIAA1549 exons 15 and 16. This antibody is predicted to detect v1 long, v1 short, v2 long, and v2 short isoforms of human KIAA1549. Species Reactivity: Human Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val1405 of human KIAA1549 protein. Antibodies are purified by peptide affinity chromatography. Background KIAA1549 is a multi-pass membrane protein primarily expressed in the central nervous system and enriched in the connecting cilium of photoreceptors (1). The human gene consists of 20 exons, with an alternate promoter within intron 8 and a variable splicing site within intron 19, yielding two short and two long isoforms (1,2). The long isoform is primarily expressed in brain tissue, and the short isoform is almost exclusively expressed in retina (1). While the endogenous function of KIAA1549 protein is still not well understood, homozygous mutations in the short KIAA1549 isoform have been observed in retinitis pigmentosa patients (1). Aberrant tandem duplications in chromosomal region 7q34 cause the expression of a novel fusion protein, combining the KIAA1549 N-terminus with the B-Raf C-terminus (2,3). The most common fusion observed is between KIAA1549 exons 1-16 and exons 9-18, though additional fusion combinations have been observed (2-4). KIAA1549::B-Raf fusion proteins are the primary drivers of low-grade juvenile pilocytic astrocytomas, the most common glioma in children (2,3). Because the inhibitory N-terminal regions of B-Raf protein are missing in these fusion proteins, unregulated downstream MEK/Erk signaling drives tumor growth (4-6). KIAA1549::B-Raf tumors have demonstrated resistance to several type 1 B-Raf inhibitors, though second-generation B-Raf inhibitors and clinical inhibitors of MEK1/2 have shown promise (7-9). Alternate Names FLJ11731; FLJ38703; FLJ40644; hypothetical protein LOC57670; K1549; KIAA1549; RP86; UPF0606 protein KIAA1549 Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 90 SOURCE: Rabbit